



PROVIDING ANSWERS FOR CANCER PATIENTS

Press release
15 October, 2021

Curasight A/S presents at Økonomisk Ugebrev Life Science Investor Conference in Copenhagen 20 October 2021

Curasight A/S CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company and its future plans at Økonomisk Ugebrev Life Science Investor Conference in Copenhagen 20 October 2021, 15:10 (CET).

The conference will be a live event with physical presentation. The conference will not be webcasted live, but will be recorded and available on Curasight's web a few days later.

For more information and registration– please [click here](#)

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.